Solbinsiran抑制ANGPTL3在临床前及早期人体研究中的效果
本研究评估N-乙酰半乳糖胺偶联siRNA药物solbinsiran抑制肝脏ANGPTL3翻译对血脂的影响。临床前小鼠和食蟹猴中ANGPTL3 mRNA及蛋白显著降低;混合型血脂异常患者单次或重复皮下给药后ANGPTL3、甘油三酯、LDL-C等致动脉粥样硬化脂蛋白呈剂量依赖性显著下降,不良事件多为轻度。
要点
- solbinsiran可显著降低肝脏ANGPTL3 mRNA及血清ANGPTL3蛋白水平。
- 混合型血脂异常患者中单次给药使甘油三酯最高降低73%±7%,LDL-C最高降低30%±16%。
- 重复给药降脂幅度更大且不良事件多为轻度,心血管结局影响待确定。
核心结论
- Solbinsiran抑制肝脏ANGPTL3翻译,在混合型血脂异常中显著降低所有致动脉粥样硬化脂蛋白。
- 该方法对心血管结局的影响尚待确定。
研究设计与样本
- 临床前研究在小鼠和食蟹猴中评估solbinsiran对ANGPTL3水平的影响。
- 1期临床研究纳入混合型血脂异常参与者,单次递增剂量研究给予solbinsiran 24-960 mg或安慰剂单次皮下注射。
- 重复给药研究在第1天和第29天给予solbinsiran 208或480 mg或安慰剂皮下注射,评估安全性和药代动力学至169天。
主要发现
- 瞬时表达人ANGPTL3的小鼠中,单次solbinsiran使肝细胞ANGPTL3 mRNA表达较溶媒组降低65%。
- 食蟹猴中,肝脏ANGPTL3 mRNA表达平均降低达73%±2%(P<0.0001),血清ANGPTL3蛋白降低达69%±4%(P<0.001)。
- 人体单次给药后,ANGPTL3自基线平均降低达86%±4%,甘油三酯降低达73%±7%,LDL-C降低达30%±16%,非HDL-C降低达41%±12%,载脂蛋白B降低达30%±11%(所有P<0.0001),高剂量效应持续。
- 重复给药后ANGPTL3降低89%±6%,甘油三酯降低达70%±13%,LDL-C降低达42%±14%,非HDL-C降低达46%±14%,载脂蛋白B降低达36%±13%(所有P<0.0001)。
- 核磁共振脂蛋白分析显示solbinsiran减少富含甘油三酯脂蛋白和LDL颗粒总数,不良事件多为轻度且与安慰剂发生率相似。
临床怎么用
- solbinsiran作为靶向ANGPTL3的siRNA,在混合型血脂异常中可显著降低甘油三酯及多种致动脉粥样硬化脂蛋白。
- 目前证据限于1期研究,尚不能用于临床决策,需等待心血管结局研究结果。
局限性
- 研究为临床前及1期临床研究,样本量小且未评估心血管结局。
- 原文未报告长期安全性数据及硬终点证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The residual cardiovascular risk associated with hypertriglyceridemia and remnant particles supports efforts to develop effective novel therapeutic approaches. Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases, and Mendelian randomization studies associate lower ANGPTL3 activity with lower triglycerides, and lower cardiovascular risk. OBJECTIVES: The aim of this study was to evaluate the impact of solbinsiran, an N-acetylgalactosamine-conjugated small interfering RNA developed to inhibit hepatic translation of ANGPTL3 messenger RNA (mRNA), on ANGPTL3 and lipid levels in preclinical models and humans. METHODS: In preclinical studies, the impact of solbinsiran on ANGPTL3 levels was assessed in mouse and nonhuman primate models. The phase 1 clinical study enrolled participants with mixed dyslipidemia. In the single-ascending-dose study, participants received single subcutaneous doses of solbinsiran (24-960 mg) or matching placebo. In the repeat-dose study, subcutaneous solbinsiran (208 or 480 mg) or matching placebo on days 1 and 29 was evaluated. Safety, pharmacokinetics, and effect on levels of ANGPTL3 and lipid parameters were evaluated over 169 days. RESULTS: In mice transiently expressing human ANGPTL3, a single dose of solbinsiran reduced hepatocyte ANGPTL3 mRNA expression by 65% vs vehicle-treated mice. In cynomolgus monkeys, mean ± SEM reductions in hepatic ANGPTL3 mRNA expression up to 73% ± 2% (P < 0.0001) and serum ANGPTL3 protein expression up to 69% ± 4% (P < 0.001) were seen vs vehicle-treated monkeys. In humans, a single dose of solbinsiran resulted in dose-dependent mean percentage reductions from baseline in ANGPTL3 up to 86% ± 4%, triglycerides up to 73% ± 7%, low-density lipoprotein (LDL) cholesterol up to 30% ± 16%, non-high-density lipoprotein cholesterol up to 41% ± 12%, and apolipoprotein B up to 30% ± 11%, with sustained effects at higher doses (P < 0.0001 for all). The repeat-dose study demonstrated reductions in ANGPTL3 of 89% ± 6%, triglycerides up to 70% ± 13%, LDL cholesterol up to 42% ± 14%, non-high-density lipoprotein cholesterol up to 46% ± 14%, and apolipoprotein B up to 36% ± 13% (P < 0.0001 for all). Nuclear magnetic resonance lipoprotein analysis demonstrated reductions in the total number of triglyceride-rich lipoprotein and LDL particles with solbinsiran. Adverse events were mostly mild in severity, with similar incidence in solbinsiran- and placebo-treated participants. CONCLUSIONS: Solbinsiran inhibits hepatic ANGPTL3 translation and results in significant reductions in all atherogenic lipoproteins in mixed dyslipidemia. The impact of this approach on cardiovascular outcomes remains to be determined. (A Study of LY3561774 in Participants With Dyslipidemia; NCT04644809).
引用
- Ray KK, Linnebjerg H, Michael LF, et al. Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies. J Am Coll Cardiol. 2025. PMID: 40158211. doi:10.1016/j.jacc.2025.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。